First in Human Clinical Trial of ApTOLL in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-18

Study Completion Date

2020-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I, first-in-human, dose ascending, randomized, placebo-controlled clinical study to assess the tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is an aptamer able to antagonize TLR4 receptor and, therefore, to reduce the inflammatory response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

NCT05569720

Stroke

COMPLETED PHASE1

Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

NCT04734548

Stroke Acute Stroke Ischemic Stroke

COMPLETED PHASE1/PHASE2

A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection

NCT06679998

Acute Ischemic Stroke (AIS)

NOT_YET_RECRUITING PHASE1

Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke

NCT00860366

Acute Ischemic Stroke

COMPLETED PHASE2/PHASE3

Thrombolysis of Urokinase for Minor Stroke

NCT04420351

Minor Stroke

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase I clinical trial is divided in two parts: the first part (part A) is a single dose escalation study and the second (part B) is a multiple dose study. Both are performed in healthy volunteers.

* First part: a single dose, i.v. administration (slow infusion), dose escalation with a maximum of 7 single dose levels, randomized, double-blind, placebo-controlled (saline solution), in healthy subjects.
* Second part: a multiple dose, i.v. administration (slow infusion), randomized, double-blind, placebo-controlled (saline solution), in healthy subjects.

The main objectives of this study are:

1. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy volunteers, after single dose administration in fasting conditions, following an ascending dosing scheme.
2. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy volunteers, after multiple dose administration in fasting conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ApTOLL single dose

ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).

Group Type ACTIVE_COMPARATOR

ApTOLL

Intervention Type DRUG

ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Placebo single dose

Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

100 mL 0.9% Sodium Chloride solution

ApTOLL multiple dose

ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).

Group Type ACTIVE_COMPARATOR

ApTOLL

Intervention Type DRUG

ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Placebo multiple dose

Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

100 mL 0.9% Sodium Chloride solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ApTOLL

ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Intervention Type DRUG

Placebo

100 mL 0.9% Sodium Chloride solution

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects (women without possibility of becoming pregnant) willing and able to give their written consent to participate in the trial.
2. Healthy subjects aged within: 18 to 55 years (limits included).
3. Clinical history and physical examination results within normality.
4. Vital signs and electrocardiogram without clinically significant pathologic abnormalities and with QTc (Corrected QT space) values lower than 450 ms.
5. Body weight between 65 and 85 kg, inclusive.
6. BMI (Body Mass Index) between 19.0 and 30.0 kg/m2.
7. No clinically significant abnormalities in haematology, biochemistry, serology (Ag HBV (Hepatitis B Virus), HCV (Hepatitis C Virus) antibodies, HIV (Human Immunodeficiency Virus) antibodies) and urine tests.

Exclusion Criteria

1. Any chronic medical condition (such as type 1 diabetes) requiring chronic treatment.
2. Evidence of active infection requiring antibiotic therapy within 14 days prior to screening.
3. Medical history of vasculitis or any autoimmune disease excluding seasonal allergic rhinitis and childhood history of atopic dermatitis.
4. Subject having at screening examination a sitting blood pressure more than or equal to 140/90 mm Hg or lower than or equal to 90/50 mmHg.
5. Subject having at screening examination a pulse more than 100 beats per minute or a body temperature more than 37.7 °C. or a respiratory rate outside the normal range of (14-20 breath per minute).
6. History of any treatment for cancer within the past 2 years, other than basal cell or squamous cell carcinoma of the skin.
7. Clinically significant abnormalities in screening laboratory tests.
8. Any prescription, over-the-counter and herbal medications within 10 days prior to study dosing.
9. Use of an investigational drug within 3 months prior to dosing in this study.
10. Psychiatric history of current or past psychosis, bipolar disorder, clinical depression, or anxiety disorder requiring chronic medication within the past 5 years.
11. Pregnant or breastfeeding women.
12. History of substance abuse, including alcohol.
13. Smokers.
14. History of substance or drug dependence, or positive urine drug screen at screening visit.
15. History of head injury.
16. History of sensitivity to any drug.
17. Having donated blood in the last month before start of the study.
18. Any reason or opinion of the investigator that would prevent the subject from participation in the study.
19. Inability to follow the instructions or an unwillingness to collaborate during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes